Chapter 8. NSAID Action and the Foundations for Cardiovascular Toxicity

  1. Giorgio Minotti
  1. Anna L. Blobaum and
  2. Lawrence J. Marnett

Published Online: 9 APR 2010

DOI: 10.1002/9780470660379.ch8

Cardiotoxicity of Non-Cardiovascular Drugs

Cardiotoxicity of Non-Cardiovascular Drugs

How to Cite

Blobaum, A. L. and Marnett, L. J. (2010) NSAID Action and the Foundations for Cardiovascular Toxicity, in Cardiotoxicity of Non-Cardiovascular Drugs (ed G. Minotti), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470660379.ch8

Editor Information

  1. University Campus Bio-Medico, CIR and Drug Sciences, and Alberto Sordi Foundation-Research Institute on Aging, Via Alvaro del Portillo 21, 00128 Rome, Italy

Author Information

  1. A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry and Pharmacology, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology and Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Publication History

  1. Published Online: 9 APR 2010
  2. Published Print: 16 APR 2010

ISBN Information

Print ISBN: 9780470772744

Online ISBN: 9780470660379

SEARCH

Keywords:

  • NSAIDs - non-steroidal anti-inflammatory drugs;
  • traditional NSAIDs - classes and evolution - asprin;
  • COX - cyclooxygenase enzyme and prostaglandins synthesis;
  • COX AND NSAID reaction mechanisms;
  • COXIBS - COX-2 selective inhibitors;
  • COX-2 discovery and COXIBS development;
  • COX-2 selective diarylheterocycle inhibitors - evolution;
  • COX-2 and arthritis trials;
  • COX-2 selective inhibitors and less gastrointestinal toxicity;
  • COX-2 and cancer, colon polyp recurrence trials

Summary

This chapter contains sections titled:

  • Introduction

  • History of Nsaids

  • Cox and Nsaid Action

  • The Discovery of Cox-2 and the development of Coxibs

  • Cox-2 and Arthritis Trials

  • Cox-2 and Cancer, Colon POLYP Recurrence Trials

  • Specific Evidence for Cox-2 Derived PGI2 Suppression and Cardiovascular Toxicity

  • Additional Mechanisms for Cardiovascular Events Related to Cox-2 Inhibition

  • Coxibs Versus NSAIDS and Cardiovascular Risk

  • Summary and Perspectives

  • References